MUMBAI, India, May 29 -- Intellectual Property India has published a patent application (202641062382 A) filed by Adichunchanagiri University; and Adichunchanagiri Institute Of Medical Sciences, Mandya, Karnataka, on May 16, for 'osteopontin marker expression by immunohistochemistry-and its correlation with various prognostic factors of invasive breast carcinoma.'
Inventor(s) include Sharifa Ayesha Fathima; and Dr Vijay Shankar S.
The application for the patent was published on May 29, under issue no. 22/2026.
According to the abstract released by the Intellectual Property India: "The present invention discloses a novel diagnostic biomarker assessment system and method for evaluating nuclear osteopontin (OPN) expression in invasive breast carcinoma to enhance prognostic accuracy and support personalized treatment strategies in breast cancer management. The proposed Osteopontin Nuclear Expression Profiling (ONEP) system integrates immunohistochemical detection of nuclear OPN-c with established clinico-pathologic and molecular markers to provide a comprehensive risk stratification tool. By quantifying nuclear OPN levels in tumor cells from surgically resected specimens, the system identifies associations with hormone receptor status and tumor behavior, offering improved predictive insights beyond conventional markers. This approach addresses limitations in current prognostic tools by enabling early identification of aggressive tumor profiles, potentially guiding targeted therapies and improving patient outcomes in resource-constrained settings, particularly among Indian women where breast cancer incidence remains high. The method demonstrates practical utility through standardized staining protocols and scoring criteria, delivering reproducible results with significant correlations to estrogen receptor (ER) and HER2 statuses while maintaining independence from certain molecular subtypes."
Disclaimer: Curated by HT Syndication.
